This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Steps Ahead: Emerging Therapies in Psoriatic Arthritis

Steps Ahead: Emerging Therapies in Psoriatic Arthritis


Slide Lecture Series

Time to Complete

1 hour


December 19, 2018


December 19, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

This activity is provided by Forefront Collaborative.

Commercial Supporter

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit

Program Description

This 60-minute online activity features real-life scenarios and relevant scientific data to provide new ideas, answers, and confidence in treating psoriatic arthritis (PsA). It consists of two concise presentations, recorded at the live workshop, a case simulation, where participants can explore a clinical vignette of a patient with psoriasis and PsA and choose treatment from the available options, and the faculty discussion of optimal clinical decisions for the simulation. Through a series of presentations and exercises, participants will cover a range of diagnosis and therapeutic options, opportunities, and outcomes to ultimately gain a deeper understanding on how to better address care gaps and move the treatment of PsA forward.

Intended Audience

The target audience is rheumatologists, nurse practitioners, and physician assistants who specialize in rheumatology. Dermatologists and other clinicians who treat patients with PsA may benefit from participation in this educational activity.

Educational Objectives

Upon completion of the activity, participants should be able to:

  • Translate evidence-based recommendations and the latest research data related to use of DMARDs in PsA into clinically meaningful information for managing patients with PsA.
  • Optimize monitoring for adherence to treatment, achievement of treatment targets, adverse events, and comorbidities in patients with PsA.
  • Develop a patient-centered approach to coordination of PsA care between rheumatology and dermatology providers.
  • Effectively engage patients with PsA in SDM regarding treatment goals, development of the treatment plan, and treatment modification.

Fee Information

There is no fee for this educational activity.

Conflict Of Interest Disclosure Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the online resources


Daniel E. Furst, MD
Professor of Rheumatology,
University of Washington School of Medicine
Seattle, Washington
David Geffen School of Medicine at UCLA
Los Angeles, California

Dr. Furst has received grant/research support from AbbVie, Actelion, Amgen, BMS Corbus, NIH, Novartis, Pfizer, Roche/Genentech. He has been a consultant for AbbVie, Actelion, Amgen, BMS, Cytori, Novartis, Pfizer, Roche/Genentech and on the speakers’ bureau of CMC Connect, (McCann Health Company)

Linda Grinnell-Merrick, MS, NP-BC
Nurse Practitioner,
Division of Allergy, Immunology, and Rheumatology
University of Rochester Medical Center
Rochester, New York

Ms. Grinnell-Merrick is on an advisory board for AbbVie, Novartis, Pfizer, Horizon; contracted research for Novartis and on the speakers’ bureau for AbbVie, Celgene, Novartis and Janssen.

Accredited Provider Disclosure

Forefront Collaborative
Christine Tebben has nothing to disclose in regards to financial relationship(s) with commercial interests.
Marianna Shershneva, MD, PhD, has nothing to disclose in regards to financial relationship(s) with commercial interests.
Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries.

The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This continuing medical education activity may include reference(s) to unlabeled or unapproved uses of drugs.


The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.


To obtain credit, a score of 100% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue